BioSpace News Archive

Drug Development

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.

March 19, 2024
·
10 min read
BioMidwest

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Forge Biologics today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101.

March 19, 2024
·
6 min read
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning

AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer.

March 19, 2024
·
2 min read
Drug Development

IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson’s Disease Psychosis

IRLAB Therapeutics AB announced that a scientific paper reporting the effects of IRLAB’s candidate drug mesdopetam in a preclinical model of Parkinson’s disease psychosis has been published in the journal Neurotherapeutics.

March 19, 2024
·
3 min read
Genetown

PureTech Proposes $100 Million Capital Return

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.

March 19, 2024
·
7 min read
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

XORTX Therapeutics Inc. is pleased to provide a summary of Company’s achievements in 2023 and objectives planned for 2024.

March 19, 2024
·
6 min read
Drug Development

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Crinetics Pharmaceuticals, Inc. announced positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.

March 19, 2024
·
10 min read
Genetown

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

March 19, 2024
·
4 min read
Policy

CGI selected by Centers for Medicare & Medicaid Services to improve Medicare access for more than 65 million beneficiaries nationwide

CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency’s Health Plan Management System.

March 19, 2024
·
8 min read
BioMidwest

Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials

Kraig Biocraft Laboratories, Inc., announces that Dr. Nirmal Kumar, a globally recognized expert in sericulture, will join the Company’s Senior Management in Vietnam to supervise the start of the spring production trials and the launch of the BAM-1 hybrid.

March 19, 2024
·
2 min read